Skip to Main Content
Table 1—

Study population description

N (%)Mean (SD)
Race   
 African-American 346 (41.7)  
 Caucasian 483 (58.3)  
Sex   
 Male 327 (39.5)  
 Female 502 (60.5)  
Age (years)  58.7 (11.5) 
Income   
 <Federal poverty 503 (60.7)  
 100–110% poverty 61 (7.4)  
 110–133% poverty 98 (11.8)  
 133–167% poverty 71 (8.6)  
 167–200% poverty 28 (3.4)  
 >200% poverty 68 (8.2)  
HbA1c level (most recent)  8.1% (2.0) 
HbA1c decrease  0.52% (2.16) 
No. HbA1c levels (20 months)  3.5 (1.6) 
No. clinic visits per year  6.6 (5.1) 
No. oral agents per patient   
 1 403 (48.6)  
 2 363 (43.8)  
 3 63 (7.6)  
Concomitant insulin 252 (30.4)  
Oral agent adherence  79.7% (21) 
Adherence to nondiabetes drugs  71.8% (17) 
Visits to single provider (continuity)  73.5% (23) 
N (%)Mean (SD)
Race   
 African-American 346 (41.7)  
 Caucasian 483 (58.3)  
Sex   
 Male 327 (39.5)  
 Female 502 (60.5)  
Age (years)  58.7 (11.5) 
Income   
 <Federal poverty 503 (60.7)  
 100–110% poverty 61 (7.4)  
 110–133% poverty 98 (11.8)  
 133–167% poverty 71 (8.6)  
 167–200% poverty 28 (3.4)  
 >200% poverty 68 (8.2)  
HbA1c level (most recent)  8.1% (2.0) 
HbA1c decrease  0.52% (2.16) 
No. HbA1c levels (20 months)  3.5 (1.6) 
No. clinic visits per year  6.6 (5.1) 
No. oral agents per patient   
 1 403 (48.6)  
 2 363 (43.8)  
 3 63 (7.6)  
Concomitant insulin 252 (30.4)  
Oral agent adherence  79.7% (21) 
Adherence to nondiabetes drugs  71.8% (17) 
Visits to single provider (continuity)  73.5% (23) 
Close Modal

or Create an Account

Close Modal
Close Modal